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Abstract: Picolinic Acid is an endogenous metabolite of L-tryptophan (TRP) that has been reported to possess a wide range 
of neuroprotective, immunological, and anti-proliferative affects within the body. However the salient physiological function 
of this molecule is yet to be established. The synthesis of picolinic acid as a product of the kynurenine pathway (KP) sug-
gests that, similar to other KP metabolites, picolinic acid may play a role in the pathogenesis of inﬂ  ammatory disorders 
within the CNS and possibly other organs.
In this paper we review the limited body of literature dealing with the physiological actions of picolinic acid in the CNS 
and its associated synthesis via the kynurenine pathway in health and disease. Discrepancies and gaps in our current knowl-
edge of picolinic acid are identiﬁ  ed highlighting areas of research to promote a more complete understanding of its endog-
enous function in the brain.
Background
Picolinic Acid (PIC) is a six-member ring structure compound (Fig. 1) that has been detected in a variety 
of biological mediums including, cell culture supernatants, blood serum
1 cerebrospinal ﬂ  uid (CSF),
2 
human milk, pancreatic juice and intestinal homogenates.
3
PIC is synthesised from L-tryptophan (TRP) via a sequent side branch of the kynurenine pathway 
(KP) involving enzymatic shunting of an aminocarboxysemialdehyde intermediate toward PIC over 
non-enzymatic synthesis of the neurotoxin quinolinic acid (QUIN) (Fig. 2). TRP catabolism via the KP 
reputedly accounts for greater than 95% of the daily TRP turnover in the CNS.
4 While a clear 
understanding of the physiological role of various KP metabolites and overall pathway dynamics remains 
elusive, at least a portion of TRP is converted to the essential pyridine nucleotide, nicotinamide adenine 
dinucleotide (NAD).
5,6
Alan Mehler
7 was the ﬁ  rst to postulate that PIC was a metabolic product of the KP. Having identiﬁ  ed 
that an enzymatic reaction perturbed the formation of PIC away from the synthesis of QUIN, Mehler 
questioned whether; a) PIC was a normal metabolic product of TRP with some physiological function 
and b) PIC production had some effect on NAD synthesis. While research has conﬁ  rmed that PIC is a 
metabolite of the KP and knowledge of other aspects of the pathway has grown considerably over recent 
years, the salient endogenous function of PIC remains elusive, with its effect on NAD metabolism and 
signiﬁ  cance in the CNS yet to be determined.
Alterations in KP metabolism have been implicated in the pathophysiology of a variety of CNS inﬂ  am-
matory diseases including; Alzheimer’s disease,
8–10 Multiple Sclerosis,
11 Parkinson’s,
12 Cerebral Malaria,
13 
Amyotropic lateral sclerosis
14 and HIV infection.
15 It is therefore reasonable to consider whether changes 
in PIC levels also correlate with either cellular or clinical pathology in any of these conditions.
In this review we discuss the potential physiological action of PIC identiﬁ  ed by previous studies and 
place these ﬁ  ndings within the context of both relevance to physiological conditions and associated KP 
metabolism. Discrepancies and gaps in our current knowledge of PIC are identiﬁ  ed and areas of research 
that may promote a more complete understanding of PIC’s endogenous function are suggested.
Physical Properties of PIC
Picolinic acid is a six-membered ring structure and isomer of nicotinic acid, containing ﬁ  ve carbon 
atoms a nitrogen and a carboxyl group at position 2.72
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A number of synonyms exist for picolinic 
acid including, Pyridine-2-carboxylic Acid; 
2-Pyridinecarboxylic acid; o-Pyridinecarboxylic 
Acid and alpha-Pyridinecarboxylic Acid. As a pure 
crystal, PIC has a melting point at ~137 
oC and is 
soluble in water to 887 g/l. The partial molal 
volume of PIC at inﬁ  nite dilution is 83.8 ml mole, 
calculated from the density of its aqueous solutions. 
The refractivity at inﬁ  nite dilultion is 31.9 ml mole. 
Picolinic acid exists mainly in the zwitterion form 
in solution and displays relatively high viscosities 
where a 48% solution has about the same 
viscosity as a 38% sucrose solution at the same 
temperature.
16
The most widely researched physical 
characteristic of picolinic acid is its efficient 
chelator properties. Chelator activity for PIC was 
ﬁ  rst reported by Weidel in 1879, where PIC was 
shown to efﬁ  ciently chelate both copper and iron. 
Later Suzuki et al
17 in 1957 reported its efﬁ  cient 
chelation of a range of metals including Ni, Zn, 
Cd, Pb and Cu.
Capitalizing on its chelation properties 
PIC-metal complexes are now widely used as a 
means of introducing bioactive metals into 
biological systems. In particular, as the element 
chromium appears to play a role in carbohydrate 
and lipid metabolism, dietary supplementation 
with chromium picolinate has been advocated in 
type 2 diabetes.
18 As chromium is not assimilated 
particularly well from the diet more effective 
absorption is achieved through the ingestion of a 
PIC-chromium chelate. Chromium picolinate 
[Cr(pic)(3)] supplementation reportedly has 
effects on blood glucose and lipid metabolism and 
body composition.
18 In these formulations PIC is 
generally considered the non-active ingredient that 
helps solubilise the metal through the formation 
of the chelate complex.
Biological Synthesis 
of Picolinic Acid
TRP can be metabolised through oxidative 
degradation via the kynurenine pathway (KP) 
to one of three main end products; kynurenic 
acid (KYNA), PIC and NAD (Fig. 2). The KP 
begins with the oxidative cleavage of the 
amino acid tryptophan by either of the two 
enzymes indoleamine 2,3-dioxygenase (IDO; 
EC 1.13.11.17) or tryptophan 2,3-dioxygenase 
also called tryptophan pyrolase (TDO; 
EC 1.13.11.11) to produce formylkynurenine 
(Fig. 2). Both IDO and TDO are haem-requiring 
enzymes and are considered rate limiting for 
this pathway.
TDO is found predominantly in mammalian 
liver and can be induced by a number of factors 
including fasting, glucocorticoids, hydrocorti-
sone, L-tryptophan and nicotinic acid.
19,20 In 
contrast IDO is found mainly in extrahepatic 
tissues including brain, placenta, spleen, lung, 
kidney, alimentary tract and epididymis.
20,21 
Unlike TDO, IDO does not contain an activating 
site for tryptophan analogues
22 and is induced 
primarily by the proinflammatory cytokine 
IFN-γ. IDO also uses the reactive oxygen inter-
mediate (ROI) superoxide as opposed to molec-
ular oxygen as a cofactor.
22 TDO also differs 
from IDO in regard to substrate specificity. 
TDO uses L-tryptophan exclusively as sub-
strate whereas IDO can metabolise both L and 
D-tryptophan as well as serotonin and other 
related indoleamines.
23
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Figure 1. Chemical structures of the isomers Picolinic acid a) and Nicotinic acid b).73
The physiological action of picolinic acid in the human brain 
International Journal of Tryptophan Research 2009:2 
In the process of PIC synthesis tryptophan
is catabolised through kynurenine to 
3-hydroxyanthranilic acid. This is then further 
acted upon by the enzyme 3-hydroxyanthranilic 
acid oxygenase (3HAO; EC 1.13.11.6), an 
enzyme present in both cytosol and synaptosomal 
fractions
24 to produce the intermediate 2-amino-
3-carboxymuconic semialdehyde (Fig. 2).
The rate limiting enzyme for PIC production 
amino-ß-carboxymuconate-semialdehyde-
decarboxylase (ACMSD; EC 4.1.1.45) will 
preferentially convert this intermediate to 
2-aminomuconic semialdehyde with subsequent 
non-enzymatic conversion to picolinic acid.
25 Non 
enzymatic rearrangement of the intermediate 
occurs when ACMSD is saturated with substrate
26 
allowing the production of quinolinic acid 
(QUIN). It has been suggested that under normal 
conditions these two pathways control equal 
ﬂ  ux.
27 ACMSD is therefore a key enzyme direct-
ing KP metabolism towards PIC production, and 
is expressed at a ratio of 1300 : 30 : 1 in kidney, 
liver and brain, respectively.
28 Not surprisingly 
the activity of ACMSD has been shown to be 
inversely proportional to the amount of NAD 
synthesised from tryptophan.
25
Physiological Role of KP 
Metabolism
In the periphery, the role of the KP appears to be 
primarily directed toward the production of NAD, 
with other KP metabolites excreted unchanged in 
high concentrations in the urine.
29 In the CNS, 
however, the purpose of KP activation is less clear. 
Generation of NAD is integral to brain function 
and may be derived de novo from tryptophan.
6 
However, KP activation potentially occurs in all 
brain cell types, including neurons,
10 astrocytes,
30 
inﬁ  ltrating macrophages,
31 dendritic cells
32 and 
blood brain barrier (BBB) endothelial cells.
33 
With many kynurenines (the collective term for 
KP metabolites) showing neuro-modulatory func-
tion in the CNS it is unclear at what point synthe-
sis and release of various kynurenines change 
from being part of normal physiological processes 
to becoming contributors to pathophysiological 
activity.
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Figure 2. The kynurenine pathway in the CNS.74
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Quinolinic acid (QUIN) and KYNA are two 
neuroactive KP metabolites that have received 
considerable attention for their modulation of the 
excitatory amino acid N-methyl-D-aspartate 
(NMDA) receptor. While QUIN shows neurotoxic 
effects by over activation of the NMDA receptor, 
KYNA offers neuro-protection by blocking 
receptor function via an allosteric glycine site.
34 
Emphasis has, therefore, been placed upon the 
importance of maintaining a balanced ratio between 
these two metabolites.
Often overlooked however, is the observation 
that PIC also shows antagonistic properties 
towards the toxic effects of QUIN via an unknown 
mechanism.
35,36 PIC’s role in maintaining the 
balance between neurotoxic and neuro-protective 
KP metabolites requires further investigation.
Experimental Actions of PIC: 
In vitro and In vivo
On its own, in experimental systems, PIC is 
reported to elicit a number of potential effects 
within the body, particularly involving immune 
function and antimicrobial activity.
In vitro studies suggest that PIC (at supernatant 
concentrations of 1–4 mM) can enhance 
macrophage effector functions through the 
enhancement of interferon-γ (INFγ) dependant 
nitric oxide synthase (NOS) gene expression
37,38 
and induce expression of the macrophage 
inﬂ  ammatory proteins (MIP)1α and 1β.
39 While 
the mechanism producing the synergism with 
IFN-γ is not known PIC mediated induction of 
MIP 1α and β is thought to be through an iron 
chelation dependant process.
High PIC concentrations (1–4 mM) have also 
been reported to selectively inhibit a variety of 
viruses in culture including the Human Immuno-
deficiency virus (HIV), Herpes Simplex virus 
(HSV), and Simian virus (SV) in culture.
40,41 PIC 
appears to produce its antiviral activity through an 
initial cytotoxic action which in turn increases 
apoptosis of infected cells and a reduction in viral 
replication.
41 PIC in combination with IFNγ has 
also been shown to inhibit retroviral expression of 
the J2 retrovirus,
42 again through an unknown 
mechanism.
Anti-microbial effects of PIC (2.5–40 mM) have 
been observed against Mycobacterium avium 
complex (MAC), with signiﬁ  cant enhancement of 
the antimicrobial action of the drugs clarithromycin, 
rifampin and various ﬂ  uoroquinolones.
43,44 It is 
suggested that as PA efﬁ  ciently chelates metal ions, 
such as Zn
2+ and Fe
2+ it is therefore likely that its 
antimicrobial activity against MAC organisms is 
due to its ability to chelate essential metal ions such 
as Fe
2+.
 43
Some investigators have also observed an effect 
of PIC on tumour growth. In vivo studies on mice 
inoculated with MBL-2 lymphoma cells showed 
that those treated with injections of PIC (100 mg/Kg) 
in combination with activated macrophages, had 
significant increases in lifespan compared to 
control.
45 These effects are arguably due to 
macrophage activation mechanisms through IFN-γ 
mediated mechanisms as suggested previously.
45
Importantly high concentrations of PIC, relative 
to physiological levels, were used in all of the 
investigations discussed above. Tables 1 and 2 
highlight the large discrepancy between PIC 
concentrations used experimentally in vitro/in vivo 
Table 1. PIC concentrations used experimentally.
Reported physiological effects of PIC [PIC] used Reference
Induces MIP 1 α & β expression
1 4000 μM 39
Enhances IFN-γ mediated NO production
1 4000 μM 37
Anti-tumour activity
2 100 mg/kg 45
Anti-viral: SV-transformed cells
1 1000–3000 μM 40
Anti-viral: HIV infected cells
1 1500–3000 μM 40
Anti-viral: J2 retrovirus
1 4000 μM 42
Anti-microbial: against MAC 2500–20000 μM 43
complex
1 2500–40000 μM 44
Experiment performed using; 
1cell culture, 
2whole animal (mouse).75
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(Table 1) and reported levels of endogenous PIC 
(Table 2). With PIC concentrations in vivo generally 
ranging within the low to mid nano (10
−9) molar 
range the milimolar (10
−3) concentrations used in 
the above cited studies have generally resulted in 
an approximately one million fold difference 
between physiological and experimental PIC con-
centrations. While these studies do indicate 
possible therapeutic roles for PIC, the large 
discrepancy between endogenous and experimental 
PIC levels does raise a question over the relevance 
of these observations to the natural physiological 
function of PIC.
PIC Concentrations in Diseases 
of the CNS
An often useful aid to understanding the 
physiological role of an uncharacterised bio-
logical molecule is the study of changes in the 
endogenous levels of the molecule in health and 
disease. Current literature in this area is however 
limited to a report by Medana et al.
13 showing 
raised PIC levels in the CSF of patients with 
cerebral malaria and a recent report from our own 
group in which no signiﬁ  cant difference in PIC 
levels were identiﬁ  ed between different CNS 
disease categories.
46 Importantly we have shown 
that any attempt at correlating PIC levels in the 
CNS may be complicated by an apparent diurnal 
ﬂ  uctuation in CSF PIC levels as discussed later 
in this review.
As PIC is part of a more complex pathway, it is 
relevant to review how other kynurenines are 
affected by disease and under what conditions 
altered levels have been observed (for summary 
see Table 3).
It has been suggested that altered KP metabo-
lism contributes signiﬁ  cantly to the pathophysio-
logy of neurodegenerative and inflammatory 
disorders of the CNS.
34 Lower levels of KYNA 
and the enzymes involved in its production have 
been found in the plasma, CSF and erythrocytes of 
Parkinson’s and Alzheimer’s disease sufferers.
9,47,48 
On the other hand, Huntington’s disease subjects 
exhibited elevated cortical QUIN levels in the early 
stages of disease onset, suggesting excitotoxicity 
as the cause of later neurodegeneration.
49
Various viral infections show an up regulation 
of the entire KP. HIV infection exhibits increased 
levels of both QUIN and TRP in the human brain,
50 
while in the CSF, QUIN has been further correlated 
to worsening brain atrophy.
51 Poliovirus infected 
macaques showed increases of CSF QUIN, KYNA, 
L-kynurenine, kynurenine-3-hydroxylase, and 
kynureninase activities, with the magnitude of 
increase correlating with the severity of observed 
motor deﬁ  cits.
52
In a study of African children suffering 
from cerebral malaria elevated PIC and QUIN 
concentrations predicted a fatal outcome to the 
disease.
13 These observations are consistent with 
results reported in an animal model using centrally 
infected (Plasmodium berghei) mice, where CSF 
PIC also increased markedly with malarial 
infection.
53
While some studies have shown that immune 
activation can result in elevated PIC levels
37–39 a 
recent study by our group failed to find any 
correlation between CSF PIC concentrations and 
CNS disease states.
46 This data was generated from 
a population of 241 patients that were suspected 
of meningitis as well as other nervous system dis-
orders. Immune activation markers such as white 
cell count and C-reactive protein also did not show 
any correlation with CSF PIC concentrations.
These results led us to investigate whether other 
biological factors may inﬂ  uence the production of 
PIC in the CNS.
Biological Factors Inﬂ  uencing PIC 
Levels in the CNS
We have recently reported that CSF PIC levels in 
the CNS may be inﬂ  uenced by both the age of the 
subject and time of sample collection.
46 This obser-
vation has not been previously reported, although 
other studies have noted similar patterns for other 
Table 2. Endogenous concentrations of PIC.
Reported endogenous PIC locations [PIC] (μM) Reference
Plasma 0.299 +/− 0.034 8
Brain (cortical tissue) 0.100–0.150 8
CSF (no brain injury) 0.017 +/− 0.005 876
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kynurenines. In a population without detectable 
neurological disease Kepplinger et al.
54 and Heyes 
et al.
9 observed that CSF KYNA levels signiﬁ    cantly 
increased with advancing age. Consistent with our 
observation, the activity of the PIC producing 
enzyme ACMSD has been shown to increase 
with age in studies of rat kidney, liver and small 
intestine.
55 Unfortunately, an investigation of age-
associated changes in ACMSD activity in human 
tissue is yet to be reported.
From a sample of subjects with no apparent 
CNS disease, we observed that CSF PIC concen-
trations display a signiﬁ  cant diurnal variation 
depending on the time of sample collection.
46 
Importantly, QUIN levels did not show this diurnal 
pattern, thus making the observation unique to PIC 
alone and suggesting the diurnal variation in 
ACMSD activity is most likely caused by substrate 
availability. Further, this circadian ﬂ  uctuation was 
not observed in CSF PIC levels from patients with 
apparent CNS disease, suggesting that this 
temporal rhythm in PIC concentrations can be 
signiﬁ  cantly perturbed during times of immune 
activation.
This observed diurnal ﬂ  uctuation is remarkably 
similar to a serial CSF sampling study of 12 healthy 
volunteers by Kennedy and colleagues.
56 A signi-
ﬁ  cant diurnal pattern in CSF TRP metabolism was 
observed, with low TRP levels at near noon, and 
a maximum reached at 11 pm—midnight.
56 
From this, it was proposed that the peak to trough 
availability of TRP as a precursor molecule may 
be of sufficient magnitude to influence other 
metabolite processes, such as melatonin secretion, 
which also follows a diurnal cycle.
56
With a diurnal ﬂ  uctuation modelled by varia-
tions in TRP levels, it can be proposed that the 
availability of TRP in the CSF has a direct affect 
on substrate availability for CNS PIC production.
Future studies are required to establish what 
conditions affect the baseline diurnal ﬂ  uctuation 
of CSF PIC and what pathophysiological/disease 
states may be linked to these changes.
Enzymatic Control of PIC 
Production: ACMSD
As the availability of substrate will impact the 
synthesis of PIC in the CNS,
56 it is relevant to 
consider whether the activity of surrounding meta-
bolic enzymes could also inﬂ  uence PIC levels.
ACMSD activity will be influenced by the 
availability of its relevant substrate which in turn 
is dependant on ﬂ  ux through the KP. The activity 
of IDO, the rate limiting enzyme of the KP, (Fig. 2) 
is therefore positioned to signiﬁ  cantly inﬂ  uence 
the synthesis of the PIC precursor.
IDO activity has been shown to be involved in a 
variety of physiological processes. IDO activation 
can influence maternal tolerance toward the 
allogenic fetus
57 regulate autoimmune disorders,
58 
and suppress transplant rejection.
59 Inhibitors of 
this enzyme are, therefore, currently being 
developed for cancer immunotherapy.
60
Table 3. Altered Kynurenine pathway metabolites in disease.
CNS disease Alteration of kynurenines in the CNS 
(CSF/brain tissueΨ)
Reference
QUIN KYNA PIC
Alzheimer’s nt nt n/s
Ψ 8
nt Ð nt 9
Parkinson’s nt Ð nt 12
Multiple sclerosis Ï
Ψ Ð nt 11
Huntington’s Ï nt nt 49
Cerebral Malaria ÏÏ Ï 13
HIV infection nt Ï nt 52
Down Syndrome nt Ï
Ψ nt 72
Amyotrophic nt Ï nt 73
lateral sclerosis Ï nt nt 14
Ï = Elevated levels compared to control, Ð = decreased levels compared to control.
Abbreviations: nt, not tested, n/s, not signiﬁ  cant.77
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While the mechanism through which IDO 
displays its immune activity appears to involve 
tryptophan concentrations in the microenvironment
57 
the inﬂ  uence of downstream metabolites such as 
PIC on these and other activities has not been 
extensively investigated.
As ACMSD substrate required for PIC synthesis 
is dependant on IDO activity, any therapeutic 
manipulation of IDO will affect the synthesis of 
PIC. Understanding the pathophysiological role of 
PIC may help prevent potential PIC associated side 
effects following IDO inhibition.
The position of ACMSD within the KP 
establishes it as the rate limiting enzyme for PIC 
synthesis (Fig. 2). Interestingly, a number of 
nutritional factors and hormonal effects have been 
observed to alter the activity of this enzyme.
High protein diets, the diabetic condition
61 and 
increased glucocorticoids
62 have all been 
demonstrated to increase the activity of ACMSD. 
Whereas high levels of dietary polyunsaturated 
fatty acids,
63 peroxisome-proliferators
64 and the 
environmental plasticizer contaminants, phthalate 
esters
65 appear to significantly down-regulate 
the activity of this enzyme.
While the physiological rationale for these 
changes is not known, high protein diets have 
previously been shown to also increase enzymes 
associated with energy metabolism.
66 Is it possible 
that ACMSD/PIC may play a role in the regulation 
glucose/energy metabolism? It is relevant to note 
that a number of metallopicolinate complexes have 
been found with insulinomimetic activity where 
the presence of the picolinate signiﬁ  cantly enhances 
the insulin sensitising activity.
67
Importantly most studies in this area have 
measured the activity of ACMSD from the 
peripheral tissue of animal models. Peripheral 
tissue data may or may not correlate substantially 
with the centrally located human protein which 
apparently has a relatively low level of expression.
28 
The lack of relevant experimental data relating to 
the human CNS highlights the need for future 
research in this area.
PIC and the BBB
The measurement of PIC in the CSF is assumed to 
reﬂ  ect endogenous PIC production within the CNS 
alone. However it is also possible that CSF levels 
may be inﬂ  uenced by transfer of PIC from the 
peripheral circulation.
Chromium picolinate is an established dietary 
supplement used to treat conditions of insulin 
resistance.
18 The ability of this complex to produce 
affects within the CNS has been queried.
68 Aggett 
et al.
69 reported that divalent metal complexes of 
PIC do not readily pass through lipid bilayers. PIC 
itself also has a relatively low partition coefﬁ  cient 
(logP = 0.098
a) reﬂ  ecting its low solubility in a 
lipophilic medium. This makes it unlikely that PIC 
would pass through the BBB on its own. In addi-
tion, Smythe and colleagues
8 reported that PIC 
plasma levels were at concentrations 3–15 times 
higher than those in the brain tissue and CSF 
(Table 2). For such a concentration ratio to be 
maintained, it is thought that limited ﬂ  ux of PIC 
occurs between the CNS and the periphery.
While the above observations indicate that CSF 
PIC levels reﬂ  ect PIC synthesis within the CNS, 
other KP metabolites may contribute signiﬁ  cantly 
to their respective cerebral pools.
In experiments using in situ brain perfusion 
techniques on rats, L-kynurenine and 3-hydroxykyn-
urenine were found to be taken up into the brain at 
signiﬁ  cant rates across the BBB via the large amino 
acid transporter.
70 Owe-Young and colleagues
33 
recently found that KP activation occurs in BBB 
endothelial cells, and when treated with INFγ, 
increased the expression of kynurenine but not 
QUIN or PIC. That these metabolites contribute to 
PIC production through increased substrate avail-
ability has been proposed but never tested.
71 It 
would be beneﬁ  cial to our understanding in this 
area if future studies examined the concentra-
tion of PIC in the CNS under conditions of both 
peripheral KP supplementation and peripheral KP 
activation.
In summary, there are a number of biological 
factors that can potentially affect PIC levels and 
synthesis in the CNS including; age and circadian 
rhythms and hormonal and nutritional factors.
However the physiological role(s) of PIC within 
the CNS is not well understood. Improved under-
standing may be achieved by characterizing the 
changes to cell/organ biochemistry/physiology at 
PIC concentrations within acceptable physiologi-
cal concetrations. In addition, it has not been 
established whether there is a link between 
PIC concentration and any disease state. 
Whether PIC production is as clearly connected to 
aLog P calculated by Advanced Chemical Development log P Batch 
version 100 software.78
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pathophysiological changes as other kynurenines 
such as QUIN and KYNA requires further inves-
tigation with careful attention to the confounding 
effects of age and diurnal rhythm.
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